InMed Pharmaceuticals Inc. 8K

InMed Pharmaceuticals amended its all‑stock merger agreement with Mentari Therapeutics and filed a Form S‑4 registration statement with the SEC in connection with the proposed merger expected to close in Q4 2026.

InMed Pharmaceuticals, Inc. announced that it has entered into an amendment to its previously disclosed all‑stock definitive merger agreement with Mentari Therapeutics, Inc., clarifying the sequencing of the contemplated merger-related transactions, the impact of pre‑closing financing on the exchange ratio, and the intended tax treatment of the merger, while leaving the remainder of the agreement in full force and effect. InMed also reported that on July 2, 2026 it filed a registration statement on Form S-4 with the SEC containing a preliminary proxy statement/prospectus and management information circular for the proposed merger, which has been approved by the boards of both InMed and Mentari and is expected to close in the fourth quarter of 2026 subject to shareholder approvals, SEC effectiveness of the S‑4, and other customary closing conditions.

Filing Facts

CIK

1728328

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-077127

Alert Tier

8